SecBot SecBot
8-K ·Filed May 8, 2026

VTGN

Vistagen Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001628280-26-032935
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Traders should monitor for topline results from PALISADE-4 expected within Q2 2026. A positive outcome could be a significant catalyst for the stock given the $23M market cap; a negative result would likely be bearish.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.6700
T+0 close · May 8, 2026 · via day close
Latest settled
−55.67%
T+60 · $0.2970
Vs SPY
−60.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $0.6700entry
  2. T+1 · 6mo ago −7.46%α −7.33% · $0.6200
  3. T+5 · 6mo ago −10.45%α −10.36% · $0.6000
  4. T+20 · 5mo ago −19.40%α −19.10% · $0.5400
  5. T+60 · 3mo ago −55.67%α −60.06% · $0.2970

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vistagen announced the completion of the last patient visit in the randomized portion of its PALISADE-4 Phase 3 trial evaluating fasedienol nasal spray for social anxiety disorder. Topline results are expected in the second quarter of 2026. This is a routine clinical milestone with no financial data disclosed.

Key Facts

  • Last patient completed last visit in randomized portion of PALISADE-4 Phase 3 trial.
  • Topline results expected in Q2 2026.
  • Open label extension (OLE) portion remains ongoing.
  • FDA Fast Track designation for fasedienol in social anxiety disorder.
  • Statistical analysis plan (SAP) refined to incorporate pre-IP SUDS as covariate; FDA had no comments.

Financial Impact

No financial data disclosed in the filing.

Risk Factors

  • No guarantee of positive trial outcome despite SAP refinements.
  • Previous PALISADE trials (1 and 3) have not been reported as positive.
  • Stock may be volatile around topline data release.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-032935
Document: pal-4lplvprex991.htm0001628280-26-032935
Document: 0001628280-26-032935-index-headers.html0001628280-26-032935
Document: 0001628280-26-032935-index.html0001628280-26-032935
Document: 0001628280-26-032935.txt0001628280-26-032935

Track record

21 reports on VTGN

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
  2. Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
  3. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  5. Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
  6. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
  7. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
  8. Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  9. Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  10. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026